Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension

Circulation

Volumn 122, Issue 5, 2010, Pages 478-487

  Noori, Muna ^a   Donald, Ann E ^b   Angelakopoulou, Aspasia ^c   Hingorani, Aroon D ^d   Williams, David J ^e  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

angiogenesis; endothelium; hypertension; preeclampsia; pregnancy

Indexed keywords

ANGIOGENIC FACTOR; BIOLOGICAL MARKER; CD135 ANTIGEN; ENDOGLIN; PLACENTAL GROWTH FACTOR;

ADULT; ARTERY DILATATION; ARTICLE; BRACHIAL ARTERY; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MATERNAL HYPERTENSION; MEAN ARTERIAL PRESSURE; PLACENTA DEVELOPMENT; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; UTERINE ARTERY;

ADULT; ANTIGENS, CD; BIOLOGICAL MARKERS; BLOOD PRESSURE; BRACHIAL ARTERY; FEMALE; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; NEOVASCULARIZATION, PHYSIOLOGIC; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY PROTEINS; PROSPECTIVE STUDIES; PULSATILE FLOW; RECEPTORS, CELL SURFACE; RISK FACTORS; UTERINE ARTERY; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 77955417702     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.895458     Document Type: Article

References (42)

1. National High Blood Pressure Education Program Working Group. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol. 2000;183:S1-S22.
2. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ. 2007;335:974-977.
3. Wallis AB, Saftlas AF, Hsia J, Atrash HK. Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987-2004. Am J Hypertens. 2008;21:521-526.
4. Hernandez-Diaz S, Toh S, Cnattingius S. Risk of pre-eclampsia in first and subsequent pregnancies: prospective cohort study. BMJ. 2009;338: b2255.
5. Khan KS, Wojdyla D, Say L, Gulmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet. 2006; 367:1066-1074.
6. Xiong X, Demianczuk NN, Saunders LD, Wang FL, Fraser WD. Impact of preeclampsia and gestational hypertension on birth weight by gesta-tional age. Am J Epidemiol. 2002;155:203-209.
7. Chappell LC, Enye S, Seed P, Briley AL, Poston L, Shennan AH. Adverse perinatal outcomes and risk factors for preeclampsia in women with chronic hypertension: a prospective study. Hypertension. 2008;51: 1002-1009.
8. Magnussen EB, Vatten LJ, Lund-Nilsen TI, Salvesen KA, Davey Smith G, Romundstad PR. Prepregnancy cardiovascular risk factors as predictors of pre-eclampsia: population based cohort study. BMJ. 2007;335: 978-981.
9. Pijnenborg R, Vercruysse L, Hanssens M. The uterine spiral arteries in human pregnancy: facts and controversies. Placenta. 2006;27:939-958.
10. Albaiges G, Missfelder-Lobos H, Lees C, Parra M, Nicolaides KH. One-stage screening for pregnancy complications by color Doppler assessment of the uterine arteries at 23 weeks' gestation. Obstet Gynecol. 2000;96:559-564.
11. Roberts JM, Taylor RN, Musci TJ. Pre-eclampsia: an endothelial cell disorder. Am J Obstet Gynecol. 1989;161:1200-1204.
12. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and pro-teinuria in preeclampsia. J Clin Invest. 2003;111:649-658.
13. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA, Stillman IE, Roberts D, D'Amore PA, Epstein FH, Sellke FW, Romero R, Sukhatme VP, Letarte M, Karumanchi SA. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12:642-649. (Pubitemid 43865232)
14. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672-683.
15. Levine RJ, Qian C, Maynard SE, Yu KF, Epstein FH, Karumanchi SA. Serum sFlt1 concentration during preeclampsia and mid trimester blood pressure in healthy nulliparous women. Am J Obstet Gynecol. 2006;194: 1034-1041.
16. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355:992-1005.
17. Chaiworapongsa T, Romero R, Espinoza J, Bujold E, Mee KY, Gon-calves LF, Gomez R, Edwin S. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia: Young Investigator Award. Am J Obstet Gynecol. 2004; 190:1541-1547.
18. Chaiworapongsa T, Romero R, Kim YM, Kim GJ, Kim MR, Espinoza J, Bujold E, Goncalves L, Gomez R, Edwin S, Mazor M. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med. 2005;17:3-18.
19. Thadhani R, Mutter WP, Wolf M, Levine RJ, Taylor RN, Sukhatme VP, Ecker J, Karumanchi SA. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab. 2004;89:770-775.
20. Rana S, Karumanchi SA, Levine RJ, Venkatesha S, Rauh-Hain JA, Tamez H, Thadhani R. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension. 2007;50:137-142.
21. Moore Simas TA, Crawford SL, Solitro MJ, Frost SC, Meyer BA, Maynard SE. Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynecol. 2007;197:244-248.
22. Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, Kusanovic JP, Gotsch F, Erez O, Mazaki-Tovi S, Gomez R, Edwin S, Chai-worapongsa T, Levine RJ, Karumanchi SA. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop pre-eclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med. 2008;21:9-23.
23. Golara M, Benedict A, Jones C, Randhawa M, Poston L, Shennan AH. Inflationary oscillometry provides accurate measurement of blood pressure in pre-eclampsia. BJOG. 2002;109:1143-1147.
24. Donald AE, Halcox JP, Charakida M, Storry C, Wallace SM, Cole TJ, Friberg P, Deanfield JE. Methodological approaches to optimize repro-ducibility and power in clinical studies of flow-mediated dilation. J Am Coll Cardiol. 2008;51:1959-1964.
25. Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB, Levy D. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001;345:1291-1297.
26. Savvidou MD, Hingorani AD, Tsikas D, Frolich JC, Vallance P, Nico-laides KH. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet. 2003;361:1511-1517.
27. Bosio PM, McKenna PJ, Conroy R, O'Herlihy C. Maternal central he-modynamics in hypertensive disorders of pregnancy. Obstet Gynecol. 1999;94:978-984.
28. Stern MP, Morales PA, Haffner SM, Valdez RA. Hyperdynamic circulation and the insulin resistance syndrome ("syndrome X"). Hypertension. 1992;20:802-808.
29. Bar J, Hod M, Erman A, Friedman S, Gelerenter I, Kaplan B, Boner G, Ovadia J. Microalbuminuria as an early predictor of hypertensive complications in pregnant women at high risk. Am J Kidney Dis. 1996;28: 220-225. (Pubitemid 26286658)
30. Kitamoto Y, Takeya M, Tokunaga H, Tomita K. Glomerular endothelial cells are maintained by vascular endothelial growth factor in the adult kidney. Tohoku. J Exp Med. 2001;195:43-54.
31. Yoshimatsu J, Matsumoto H, Goto K, Shimano M, Narahara H, Miyakawa I. Relationship between urinary albumin and serum soluble fms-like tyrosine kinase 1 (sFlt-1) in normal pregnancy. Eur J Obstet Gynecol Reprod Biol. 2006;128:204-208.
32. Holston AM, Qian C, Yu KF, Epstein FH, Karumanchi SA, Levine RJ. Circulating angiogenic factors in gestational proteinuria without hypertension. Am J Obstet Gynecol. 2009;200:392-410.
33. Torry DS, Hinrichs M, Torry RJ. Determinants of placental vascularity. Am J Reprod Immunol. 2004;51:257-268.
34. Wallner W, Sengenberger R, Strick R, Strissel PL, Meurer B, Beckmann MW, Schlembach D. Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction. Clin Sci (Lond). 2007;112:51-57.
35. Poon LC, Kametas NA, Maiz N, Akolekar R, Nicolaides KH. First-trimester prediction of hypertensive disorders in pregnancy. Hypertension. 2009;53: 812-818.
36. Maynard S, Epstein FH, Karumanchi SA. Preeclampsia and angiogenic imbalance. Annu Rev Med. 2008;59:61-78.
37. Savvidou MD, Noori M, Anderson JM, Hingorani AD, Nicolaides KH. Maternal endothelial function and serum concentrations of placental growth factor and soluble endoglin in women with abnormal placentation. Ultrasound Obstet Gynecol. 2008;32:871-876.
38. ten Dijke P, Goumans MJ, Pardali E. Endoglin in angiogenesis and vascular diseases. Angiogenesis. 2008;11:79-89.
39. Boegehold MA. Heterogeneity of endothelial function within the circulation. Curr Opin Nephrol Hypertens. 1998;7:71-78.
40. Agatisa PK, Ness RB, Roberts JM, Costantino JP, Kuller LH, McLaughlin MK. Impairment of endothelial function in women with a history of preeclampsia: an indicator of cardiovascular risk. Am J Physiol Heart Circ Physiol. 2004;286:H1389-H1393.
41. Khurana R, Moons L, Shafi S, Luttun A, Collen D, Martin JF, Carmeliet P, Zachary IC. Placental growth factor promotes atherosclerotic intimal thickening and macrophage accumulation. Circulation. 2005;111: 2828-2836.
42. Cassidy A, Chiuve SE, Manson JE, Rexrode KM, Girman CJ, Rimm EB. Potential role for plasma placental growth factor in predicting coronary heart disease risk in women. Arterioscler Thromb Vasc Biol. 2009;29:134-139.